JP2011501672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501672A5 JP2011501672A5 JP2010530102A JP2010530102A JP2011501672A5 JP 2011501672 A5 JP2011501672 A5 JP 2011501672A5 JP 2010530102 A JP2010530102 A JP 2010530102A JP 2010530102 A JP2010530102 A JP 2010530102A JP 2011501672 A5 JP2011501672 A5 JP 2011501672A5
- Authority
- JP
- Japan
- Prior art keywords
- pxr
- fragment
- protein
- receptor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010001511 Pregnane X Receptor Proteins 0.000 claims description 53
- 102000000804 Pregnane X Receptor Human genes 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000011830 transgenic mouse model Methods 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940000406 drug candidate Drugs 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 102100037473 Glutathione S-transferase A1 Human genes 0.000 claims description 4
- 101001026125 Homo sapiens Glutathione S-transferase A1 Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 230000006461 physiological response Effects 0.000 claims description 4
- 239000000823 artificial membrane Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- QHSMEGADRFZVNE-UHFFFAOYSA-N 1-hydroxymidazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CO)=NC=C2CN=C1C1=CC=CC=C1F QHSMEGADRFZVNE-UHFFFAOYSA-N 0.000 claims description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 2
- 101100187477 Homo sapiens NR1I2 gene Proteins 0.000 claims description 2
- -1 MRP2 Proteins 0.000 claims description 2
- 101000836282 Mus musculus Solute carrier organic anion transporter family member 1C1 Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 230000009266 disease activity Effects 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003793 midazolam Drugs 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 229940076376 protein agonist Drugs 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims description 2
- 229960003040 rifaximin Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000003827 upregulation Effects 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 4
- 241000699660 Mus musculus Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99923407P | 2007-10-17 | 2007-10-17 | |
| PCT/US2008/080115 WO2009052255A2 (en) | 2007-10-17 | 2008-10-16 | Novel therapeutic targets in bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501672A JP2011501672A (ja) | 2011-01-13 |
| JP2011501672A5 true JP2011501672A5 (enExample) | 2011-12-01 |
Family
ID=40568065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530102A Pending JP2011501672A (ja) | 2007-10-17 | 2008-10-16 | 腸疾患における新規な治療上の標的 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110055943A1 (enExample) |
| EP (1) | EP2201372A4 (enExample) |
| JP (1) | JP2011501672A (enExample) |
| CN (1) | CN101896815A (enExample) |
| AU (1) | AU2008312464A1 (enExample) |
| MX (1) | MX2010004333A (enExample) |
| WO (1) | WO2009052255A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| HRP20140939T1 (hr) * | 2008-05-07 | 2014-11-21 | Salix Pharmaceuticals, Ltd. | Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva |
| CN108267522A (zh) * | 2017-12-28 | 2018-07-10 | 北京和合医学诊断技术股份有限公司 | 检测血液中奥氮平药物含量的液相色谱分析方法 |
| CN110470771B (zh) * | 2019-09-05 | 2021-06-01 | 清华大学 | 一种评价转基因植物食用安全性的方法 |
| CN117031004B (zh) * | 2023-08-09 | 2024-10-01 | 四川省医学科学院·四川省人民医院 | 一种检测网膜素-1的试剂在制备预测或评估ibs患者生活质量的产品中的应用 |
-
2008
- 2008-10-16 US US12/682,665 patent/US20110055943A1/en not_active Abandoned
- 2008-10-16 WO PCT/US2008/080115 patent/WO2009052255A2/en not_active Ceased
- 2008-10-16 EP EP08839346A patent/EP2201372A4/en not_active Withdrawn
- 2008-10-16 AU AU2008312464A patent/AU2008312464A1/en not_active Abandoned
- 2008-10-16 CN CN2008801210743A patent/CN101896815A/zh active Pending
- 2008-10-16 JP JP2010530102A patent/JP2011501672A/ja active Pending
- 2008-10-16 MX MX2010004333A patent/MX2010004333A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bi et al. | The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor | |
| Ma et al. | Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes | |
| DeWire et al. | β-arrestin-mediated signaling regulates protein synthesis | |
| Srodulski et al. | Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin | |
| Nie et al. | The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer | |
| Nishiura et al. | PKA activation and endothelial claudin-5 breakdown in the schizophrenic prefrontal cortex | |
| Wang et al. | Transcription factor ATF5 is required for terminal differentiation and survival of olfactory sensory neurons | |
| Bolognin et al. | An experimental rat model of sporadic Alzheimer’s disease and rescue of cognitive impairment with a neurotrophic peptide | |
| Kiefel et al. | Linking L1CAM-mediated signaling to NF-κB activation | |
| Abou Ziki et al. | The interplay of canonical and noncanonical Wnt signaling in metabolic syndrome | |
| WO2011094535A2 (en) | Biomarkers of aging for detection and treatment of disorders | |
| Sheng et al. | Smad3 deficiency promotes beta cell proliferation and function in db/db mice via restoring Pax6 expression | |
| Lu et al. | A role for Kalirin-7 in nociceptive sensitization via activity-dependent modulation of spinal synapses | |
| Wang et al. | Increasing expression of substance P and calcitonin gene-related peptide in synovial tissue and fluid contribute to the progress of arthritis in developmental dysplasia of the hip | |
| CN101946008A (zh) | 用于控制血管生成的方法 | |
| Chen et al. | Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease | |
| Schaffenrath et al. | Characterization of the blood–brain barrier in genetically diverse laboratory mouse strains | |
| Boudes et al. | Crucial role of TRPC1 and TRPC4 in cystitis-induced neuronal sprouting and bladder overactivity | |
| JP2011501672A5 (enExample) | ||
| Ling et al. | Raf kinase inhibitory protein (RKIP): functional pleiotropy in the mammalian brain | |
| Li et al. | p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease | |
| Mucunguzi et al. | Identification of the principal transcriptional regulators for low-fat and high-fat meal responsive genes in small intestine | |
| Kanaan et al. | The longitudinal transcriptomic response of the substantia nigra to intrastriatal 6-hydroxydopamine reveals significant upregulation of regeneration-associated genes | |
| Justinich et al. | The extracellular calcium-sensing receptor (CaSR) on human esophagus and evidence of expression of the CaSR on the esophageal epithelial cell line (HET-1A) | |
| Regner et al. | Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents |